Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OrganoClick AB's change in receivables for the quarter that ended in Mar. 2026 was kr-10.60 Mil. It means OrganoClick AB's Accounts Receivable
increased by kr10.60 Mil
from Dec. 2025 to Mar. 2026 .
OrganoClick AB's change in receivables for the fiscal year that ended in Dec. 2025 was kr2.59 Mil. It means OrganoClick AB's Accounts Receivable
declined by kr2.59 Mil
from Dec. 2024 to Dec. 2025 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
OrganoClick AB's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 62.44.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. OrganoClick AB's liquidation value for the
three
months ended in Mar. 2026 was kr-99.02 Mil.
OrganoClick AB (OSTO:ORGC) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
OrganoClick AB's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrganoClick AB Change In Receivables Related Terms
OrganoClick AB Change In Receivables Historical Data
* Premium members only.
The historical data trend for OrganoClick AB's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr11.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of kr11.38 Mil mean?
OrganoClick AB (OSTO:ORGC) has a Change In Receivables of kr11.38 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for OrganoClick AB and its competitors.
Is OrganoClick AB's Change In Receivables too high?
OrganoClick AB's current Change In Receivables is kr11.38 Mil. Overall, OrganoClick AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OrganoClick AB's Change In Receivables compare to LIN and SHW?
OrganoClick AB's Change In Receivables of kr11.38 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Chemicals company?
A good Change In Receivables depends on the Chemicals industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for OrganoClick AB and its competitors. OrganoClick AB's current Change In Receivables is kr11.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrganoClick AB stock overvalued right now?
Based on GuruFocus' analysis, OrganoClick AB (OSTO:ORGC) is currently considered Possible Value Trap. The stock's GF Value™ is kr1.90, compared to a current price of kr0.42 — trading 77.7% below its estimated fair value. The current Change In Receivables is kr11.38 Mil. OrganoClick AB's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For OrganoClick AB (OSTO:ORGC), the current Change In Receivables is kr11.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OrganoClick AB (OSTO:ORGC) Overvalued in 2026?
Based on GuruFocus' analysis, OrganoClick AB stock appears to be undervalued.
The current stock price of kr0.42 is trading 77.7% below its estimated GF Value™ of kr1.90.
GuruFocus considers OrganoClick AB to be Possible Value Trap.
Key valuation signals for OSTO:ORGC:
Change In Receivables: kr11.38 Mil
GF Value™: kr1.90 vs. price of kr0.42 (77.7% below fair value)
No single metric tells the full story. See the OSTO:ORGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OrganoClick AB is involved in the chemicals industry. Its product portfolio includes green chemical technologies for creating water repellency, biobased binders for increasing the mechanical strength, and wood treatment products for resistance to fungal degradation and resistance to fire. It operates in four business areas Functional Wood, Green coatings & maintenance products, Nonwoven & technical textile, and Other. The group has a single operating segment.
28GF Score
Get the complete analysis for OSTO:ORGC
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ORGC has been successfully added to your 
